The total value of the offer based on all outstanding shares in Abliva amounts to approximately SEK 725.3 million (USD 66.1 million). The three major shareholders of Abliva, holding in aggregate approximately 49.82 percent of the total number of shares and votes in Abliva, have undertaken to accept the offer, subject to customary conditions.
Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. Abliva’s portfolio includes projects at different stages and ranges from early discovery phase to clinical phase. This transaction aligns with Pharming Group’s vision to become a leading global rare disease company of choice for patients and partners with a specific focus on transformative medicines in rare diseases, serving unserved rare disease patients. By integrating Abliva’s advanced project – KL1333, a powerful regulator of essential co-enzymes NAD+ and NADH in late-stage development – Pharming Group aims to accelerate the availability of this promising treatment.
The NautaDutilh team further consisted of Dineth de Graaf, Jafar Alhashime, Annefleur van Oel, Auke Knigge, Petra Zijp, Victorine Dijkstra, Céline Hennink, Lauren Delleman, Nicoline Welzenbagh, and Jinne van Belle.
NautaDutilh acts as legal advisor to longstanding client Pharming Group and is working together with Mannheimer Swartling Advokatbyrå for Swedish law aspects of the offer.